Tirzepatide
Tirzepatide (GIP/GLP-1 Dual Agonist)
Tirzepatide is a first-in-class dual agonist for both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. FDA-approved as Mounjaro (diabetes) and Zepbound (weight management), it has demonstrated superior weight reduction outcomes to semaglutide in head-to-head data, with mean losses exceeding 20% in SURMOUNT-1.
Mechanism of Action
Tirzepatide's dual mechanism differentiates it from pure GLP-1 agonists. The GIP component contributes additional appetite suppression via hypothalamic GIP receptors and improves insulin secretion efficiency. The two incretin pathways appear to interact synergistically — each amplifying the other's effects at the receptor level.
Unlike GLP-1 receptors, GIP receptors are also found in adipocytes. GIP receptor activation in fat tissue may directly influence lipid metabolism and fat storage patterns, potentially contributing to the enhanced body composition changes observed with tirzepatide versus GLP-1 monotherapy.
The C20 fatty diacid linker on tirzepatide allows albumin binding, extending half-life to approximately 5 days and enabling weekly dosing. The molecule was designed to have balanced potency at both receptor types, unlike earlier dual agonists that favoured one receptor.
Research Evidence
Tirzepatide's clinical development programme (SURPASS for diabetes, SURMOUNT for obesity) has consistently demonstrated superior weight loss outcomes to comparator GLP-1 agonists. The SURMOUNT-1 trial set a new benchmark for pharmacological weight management.
SURMOUNT-1: Tirzepatide for Obesity Treatment
2,539 adults without diabetes; tirzepatide 15mg produced mean weight reduction of 20.9% at 72 weeks. 57% of 15mg group lost ≥20% body weight — outcomes approaching those of bariatric surgery.
SURPASS-2: Tirzepatide vs Semaglutide in Type 2 Diabetes
Head-to-head comparison showing tirzepatide 15mg produced significantly greater HbA1c and weight reductions vs semaglutide 1mg across all doses tested.
Typical Research Protocol
Titration: 2.5mg × 4 weeks, increase by 2.5mg every 4 weeks as tolerated to target dose (5mg, 10mg, or 15mg). Slower titration significantly reduces GI adverse effects.
Safety Profile
Reported Side Effects
- Nausea (33–40%)
- Diarrhoea (17–22%)
- Vomiting (11–13%)
- Constipation (11–12%)
- Decreased appetite
- Injection site reactions
Contraindications
- Personal/family history of MEN2 or medullary thyroid carcinoma
- Known GIP or GLP-1 receptor agonist hypersensitivity
- Severe renal impairment (caution)
- Pregnancy
- Pancreatitis history
Common Research Stacks
Frequently Asked Questions
Is tirzepatide stronger than semaglutide?
Clinical trial data show tirzepatide 15mg produces greater average weight loss (~21%) than semaglutide 2.4mg (~15%). However, individual responses vary significantly. Tolerability profiles are similar; tirzepatide may have a slightly lower rate of nausea at comparable efficacy doses. The choice between them typically depends on insurance coverage, individual response, and prescriber preference.
What is the difference between Mounjaro and Zepbound?
Both are the same molecule (tirzepatide) but with different FDA-approved indications. Mounjaro is approved for type 2 diabetes management. Zepbound is the higher-dose formulation approved for chronic weight management in adults with BMI ≥30, or ≥27 with a weight-related comorbidity.
How quickly does tirzepatide produce weight loss?
In SURMOUNT-1, meaningful weight loss was observed by week 4–8, with the trajectory steepening through the titration phase. Maximum effect is typically seen at 52–72 weeks when participants reach and stabilise at their target dose. The first 20 weeks (titration phase) often show the most rapid loss as appetite suppression is established.
Can tirzepatide cause muscle loss?
Rapid weight loss from any intervention carries some risk of lean mass reduction. In SURMOUNT trials, approximately 25–40% of total weight lost was lean mass — a proportion comparable to dietary restriction alone. Resistance training and adequate protein intake during tirzepatide therapy are strongly recommended to preserve muscle mass during the weight-loss phase.
What are the most common reasons people stop tirzepatide?
GI adverse effects (nausea, vomiting, diarrhoea, constipation) are the most common reasons for discontinuation, typically most severe during dose escalation. Slow titration — staying at each dose step for 4–8 weeks instead of the minimum 4 — significantly reduces discontinuation rates. Cost and insurance access are also major real-world barriers to continuation.
Key Research References
- Jastreboff AM et al. (2022). Tirzepatide once weekly for the treatment of obesity. N Engl J Med.
- Frias JP et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med.
Explore more Weight Loss research compounds
Browse Weight Loss →